Reviva Pharmaceuticals Receives Nasdaq Delisting Notice

Reviva Pharmaceuticals Holdings Inc. received a notice from Nasdaq on May 12 2026 stating the company does not satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market, according to an 8-K filed with the SEC on May 13 2026.

The company, ticker RVPH, has 180 calendar days from the date of the notice to regain compliance. Under Nasdaq Listing Rule 5550(a)(2), the bid price of RVPH common stock must close at or above $1.00 per share for a minimum of 10 consecutive business days during that period.

The notice provides no immediate delisting; the company retains its listing through the compliance window that closes on November 10 2026.

Prior to the notice the company operated under full Nasdaq Capital Market listing standards. The new state triggers a formal monitoring period during which Reviva must either achieve the required consecutive closing prices or submit a plan to regain compliance.

If the company fails to regain compliance by the end of the 180-day period and does not qualify for a second 180-day extension under applicable Nasdaq rules, its common stock will be subject to delisting. A separate Form 25 would then be filed to effect removal from the exchange.

The delisting notice requires Reviva to evaluate strategic options including a potential reverse stock split to lift the share price above the $1.00 threshold. The company must also consider the impact on existing contractual obligations, such as registration rights or warrant agreements that reference continued exchange listing.

A failure to regain compliance would force the stock to trade on over-the-counter markets, triggering notification obligations to shareholders and counterparties under various financing agreements. Nasdaq may also require additional public disclosures or filings related to the compliance plan.

This marks the first delisting notice issued to Reviva Pharmaceuticals Holdings since its 2020 business combination and Nasdaq listing. The filing cites only Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard and Item 8.01 Other Events; no further financial or clinical details were disclosed in the document.